These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 33199881)

  • 1. Efficacy and safety of esaxerenone (CS-3150), a newly available nonsteroidal mineralocorticoid receptor blocker, in hypertensive patients with primary aldosteronism.
    Satoh F; Ito S; Itoh H; Rakugi H; Shibata H; Ichihara A; Omura M; Takahashi K; Okuda Y; Iijima S
    Hypertens Res; 2021 Apr; 44(4):464-472. PubMed ID: 33199881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antihypertensive effects and safety of esaxerenone in patients with moderate kidney dysfunction.
    Ito S; Itoh H; Rakugi H; Okuda Y; Iijima S
    Hypertens Res; 2021 May; 44(5):489-497. PubMed ID: 33323991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study.
    Ito S; Itoh H; Rakugi H; Okuda Y; Yamakawa S
    J Hum Hypertens; 2019 Jul; 33(7):542-551. PubMed ID: 31113987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term phase 3 study of esaxerenone as mono or combination therapy with other antihypertensive drugs in patients with essential hypertension.
    Rakugi H; Ito S; Itoh H; Okuda Y; Yamakawa S
    Hypertens Res; 2019 Dec; 42(12):1932-1941. PubMed ID: 31554937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of esaxerenone on blood pressure, urinary albumin excretion, serum levels of NT-proBNP, and quality of life in patients with primary aldosteronism.
    Yoshida Y; Fujiwara M; Kinoshita M; Sada K; Miyamoto S; Ozeki Y; Iwamoto M; Mori Y; Nagai S; Matsuda N; Noguchi T; Okamoto M; Gotoh K; Masaki T; Shibata H
    Hypertens Res; 2024 Jan; 47(1):157-167. PubMed ID: 37717115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Esaxerenone in Hypertensive Patients with Left Ventricular Hypertrophy (ESES-LVH) Study: A Multicenter, Open-Label, Prospective, Interventional Study.
    Yamamoto E; Usuku H; Sueta D; Suzuki S; Nakamura T; Matsui K; Matsushita K; Iwasaki T; Sakaino N; Sakanashi T; Hirayama K; Kurokawa H; Kikuta K; Yamamoto N; Sato K; Tokitsu T; Taguchi T; Shiosakai K; Sugimoto K; Tsujita K;
    Adv Ther; 2024 Mar; 41(3):1284-1303. PubMed ID: 38310194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of dosage-escalation of low-dosage esaxerenone added to a RAS inhibitor in hypertensive patients with type 2 diabetes and albuminuria: a single-arm, open-label study.
    Itoh H; Ito S; Rakugi H; Okuda Y; Nishioka S
    Hypertens Res; 2019 Oct; 42(10):1572-1581. PubMed ID: 31239535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploratory study on the relationship between urinary sodium/potassium ratio, salt intake, and the antihypertensive effect of esaxerenone: the ENaK Study.
    Katsuya T; Inobe Y; Uchiyama K; Nishikawa T; Hirano K; Kato M; Fukui T; Hatta T; Iwasaki A; Ishii H; Sugiura T; Taguchi T; Tanabe A; Sugimoto K; Shimosawa T;
    Hypertens Res; 2024 Apr; 47(4):835-848. PubMed ID: 38212366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study).
    Ito S; Itoh H; Rakugi H; Okuda Y; Yoshimura M; Yamakawa S
    Hypertension; 2020 Jan; 75(1):51-58. PubMed ID: 31786983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic reduction in albuminuria in type 2 diabetic mice by esaxerenone (CS-3150), a novel nonsteroidal selective mineralocorticoid receptor blocker, combined with an angiotensin II receptor blocker.
    Arai K; Morikawa Y; Ubukata N; Sugimoto K
    Hypertens Res; 2020 Nov; 43(11):1204-1213. PubMed ID: 32616846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the novel nonsteroidal mineralocorticoid receptor blocker, esaxerenone (CS-3150), on blood pressure and urinary angiotensinogen in low-renin Dahl salt-sensitive hypertensive rats.
    Li L; Guan Y; Kobori H; Morishita A; Kobara H; Masaki T; Nakano D; Nishiyama A
    Hypertens Res; 2019 Jun; 42(6):769-778. PubMed ID: 30587856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Esaxerenone, a novel nonsteroidal mineralocorticoid receptor blocker (MRB) in hypertension and chronic kidney disease.
    Wan N; Rahman A; Nishiyama A
    J Hum Hypertens; 2021 Feb; 35(2):148-156. PubMed ID: 32661269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Esaxerenone in Hypertensive Patients with Diabetic Kidney Disease: A Multicenter, Open-Label, Prospective Study.
    Uchida HA; Nakajima H; Hashimoto M; Nakamura A; Nunoue T; Murakami K; Hosoya T; Komoto K; Taguchi T; Akasaka T; Shiosakai K; Sugimoto K; Wada J;
    Adv Ther; 2022 Nov; 39(11):5158-5175. PubMed ID: 36070133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of the Nonsteroidal Mineralocorticoid Receptor Blocker, Esaxerenone, on Nocturnal Hypertension: A Post Hoc Analysis of the ESAX-HTN Study.
    Kario K; Ito S; Itoh H; Rakugi H; Okuda Y; Yoshimura M; Yamakawa S
    Am J Hypertens; 2021 May; 34(5):540-551. PubMed ID: 33165570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Patient with Bilateral Primary Aldosteronism Refractory to Oral Eplerenone Who Responded to Esaxerenone with Increased Renin Activity.
    Okamura K; Matsushima M; Yamamoto F; Takamiya Y; Okuda T; Shirai K; Okamura K; Urata H
    Am J Case Rep; 2020 Jan; 21():e920615. PubMed ID: 31907345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antihypertensive Effect of Long-Term Monotherapy with Esaxerenone in Patients with Essential Hypertension: Relationship Between Baseline Urinary Sodium Excretion and Its Antihypertensive Effect.
    Ichikawa S; Tsutsumi J; Sugimoto K; Yamakawa S
    Adv Ther; 2022 Oct; 39(10):4779-4791. PubMed ID: 35976603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of esaxerenone (CS-3150) in Japanese patients with type 2 diabetes and macroalbuminuria: a multicenter, single-arm, open-label phase III study.
    Ito S; Kashihara N; Shikata K; Nangaku M; Wada T; Okuda Y; Sawanobori T
    Clin Exp Nephrol; 2021 Oct; 25(10):1070-1078. PubMed ID: 34110524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exposure-response analysis of the efficacy and safety of esaxerenone, a novel nonsteroidal mineralocorticoid receptor blocker, in hypertensive patients with or without diabetic kidney disease.
    Yoshihara K; Fukae M; Kastrissios H; Wada R; Shimizu T
    Drug Metab Pharmacokinet; 2024 Apr; 55():100535. PubMed ID: 38245949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of esaxerenone in Japanese hypertensive patients with heart failure with reduced ejection fraction: A retrospective study.
    Iwahana T; Saito Y; Okada S; Kato H; Ono R; Kobayashi Y
    PLoS One; 2021; 16(11):e0259485. PubMed ID: 34748605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacological profile, clinical efficacy, and safety of esaxerenone (Minnebro
    Yamakawa S; Homma T; Yamada M; Igawa Y; Yoshimura M
    Nihon Yakurigaku Zasshi; 2020; 155(5):340-350. PubMed ID: 32879177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.